ROVI announces an agreement with Biogaran for the marketing of its enoxaparin biosimilar in France


No votes yet
 
Related
Madrid, 29 October 2026   Laboratorios Farmacéuticos ROVI expresses its deepest sorrow at the passing of Ms Fátima Báñez García, an...
2 min
29/10/2026
Total revenue amounted to 357.0 million euros in the first half of 2026, up 13.2% compared to 315.3 million euros in the same period of...
4 min
23/07/2026
Today, Laboratorios Farmacéuticos ROVI, S.A. (“ROVI”) has signed a Protocol of Intentions with the Regional Government of Castilla-La...
3 min
08/07/2026